Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 37 |
| Active Pipeline (Recruiting Now) | 26 (14) |
| Completed vs Stopped Early | 5 / 0 (0.0%) |
| Median Closed Actual Enrollment | 144 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Guangdong Provincial People's Hospital | Guangzhou | 19 |
| The First Affiliated Hospital of Guangzhou Medical University | Guangzhou, Guangdong | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06451861 | Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML | Phase II | RECRUITING |
| NCT04946734 | Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine | Phase III | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Guangdong Provincial People's Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.